Investors
and Media
News Releases
-
Feb 1, 2019
SOUTH SAN FRANCISCO, Calif., Feb. 01, 2019 (GLOBE NEWSWIRE) -- Portola Pharmaceuticals, Inc.® (NASDAQ: PTLA) today announced that it will host a webcast and conference call to discuss the...
-
Jan 30, 2019Results to be presented on Thursday, February 7, 2019 at 11:36 a.m. HST/4:36 p.m. EST
SOUTH SAN FRANCISCO, Calif., Jan. 30, 2019 (GLOBE NEWSWIRE) -- Portola Pharmaceuticals, Inc.® (Nasdaq: PTLA) today announced that full results from the Company’s ANNEXA-4 study of Andexxa®...
-
Jan 28, 2019Brings to Portola 30 Years’ Commercial Experience and Key Therapeutic Area Launch Expertise
SOUTH SAN FRANCISCO, Calif., Jan. 28, 2019 (GLOBE NEWSWIRE) -- Portola Pharmaceuticals, Inc.® (Nasdaq: PTLA) today announced the appointment of Sheldon Koenig as executive vice president and...
-
Dec 31, 2018– Expands Patient Access to Andexxa, the First and Only Antidote for Reversal of the Factor Xa Inhibitors Rivaroxaban or Apixaban –
SOUTH SAN FRANCISCO, Calif., Dec. 31, 2018 (GLOBE NEWSWIRE) -- Portola Pharmaceuticals, Inc.® (Nasdaq: PTLA) today announced that the U.S. Food and Drug Administration (FDA) has approved the...
-
Dec 18, 2018
SOUTH SAN FRANCISCO, Calif., Dec. 18, 2018 (GLOBE NEWSWIRE) -- Portola Pharmaceuticals, Inc.® (Nasdaq: PTLA) today announced that Scott Garland, Portola’s president and chief executive officer,...